RT Journal Article
T1 Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
A1 de Miguel-Perez, Diego
A1 Russo, Alessandro
A1 Arrieta, Oscar
A1 Ak, Murat
A1 Barron, Feliciano
A1 Gunasekaran, Muthukumar
A1 Mamindla, Priyadarshini
A1 Lara-Mejia, Luis
A1 Peterson, Christine B
A1 Er, Mehmet E
A1 Peddagangireddy, Vishal
A1 Buemi, Francesco
A1 Cooper, Brandon
A1 Manca, Paolo
A1 Lapidus, Rena G
A1 Hsia, Ru-Ching
A1 Cardona, Andres F
A1 Naing, Aung
A1 Kaushal, Sunjay
A1 Hirsch, Fred R
A1 Mack, Philip C
A1 Serrano, Maria Jose
A1 Adamo, Vincenzo
A1 Colen, Rivka R
A1 Rolfo, Christian
K1 Biomarkers
K1 Extracellular vesicles
K1 Immunotherapy
K1 NSCLC
K1 PD-L1
AB Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs.
YR 2022
FD 2022-06-02
LK http://hdl.handle.net/10668/20349
UL http://hdl.handle.net/10668/20349
LA en
DS RISalud
RD Apr 9, 2025